FDA's Approach to Regulating Biosimilars

Area of Science:

• Pharmaceutical Science
• Regulatory Science
• Biotechnology

Background:

• The Biologics Price Competition and Innovation (BPCI) Act established a regulatory pathway for biosimilars in the United States.
• Biosimilars are biological products highly similar to FDA-licensed reference products, with no clinically meaningful differences.
• The U.S. Food and Drug Administration (FDA) regulates biosimilars based on the BPCI Act requirements.

Purpose of the Study:

• To outline the FDA's regulatory framework for biosimilar and interchangeable biological products.
• To explain the scientific and regulatory standards for demonstrating biosimilarity.
• To assure healthcare professionals and patients about the safety and efficacy of biosimilars.

Main Methods:

• The development of biosimilars relies on analytical similarity assessments comparing structural, physicochemical, and functional properties.
• Clinical studies, including immunogenicity and pharmacokinetic/pharmacodynamic assessments, evaluate for clinically meaningful differences.
• The FDA's rigorous standards for safety and efficacy must be met for biosimilar approval.

Main Results:

• Biosimilar products are demonstrated to be highly similar to their reference products.
• Minor differences in inactive components are permissible if they do not impact safety, purity, or potency.
• No clinically meaningful differences in safety, purity, and potency exist between biosimilars and reference products.

Conclusions:

• Biosimilar products are approved based on a comprehensive data package demonstrating high similarity and no clinically meaningful differences.
• Patients and healthcare providers can rely on the safety and effectiveness of biosimilars in the same way as reference products.
• The regulatory pathway ensures that biosimilars provide safe, effective, and high-quality treatment options.